VRDN

SEC source: 0001193125-26-359636 · ownership.xml · derivative · entry 4

Tousignant Jennifer · CIK 0002010978 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 114,072

Underlying: Common Stock · 10,000 shares

Expires 2035-03-03

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: The option was granted on March 3, 2025 and vests in 48 equal monthly installments following the date of the grant, subject to the Reporting Person's continued service to Issuer through each vesting date.

SEC source: 0001193125-26-359636 · ownership.xml · nonDerivative · entry 3

Tousignant Jennifer · CIK 0002010978 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

SEC source: 0001193125-26-359636 · ownership.xml · nonDerivative · entry 2

Tousignant Jennifer · CIK 0002010978 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001193125-26-359636 · ownership.xml · nonDerivative · entry 1

Tousignant Jennifer · CIK 0002010978 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

F1 · shares: The shares sold include 718 shares previously acquired by the reporting person pursuant to the Viridian Therapeutics, Inc. Employee Stock Purchase Plan in a transaction that was exempt under Rule 16b-3(c).

SEC source: 0001193125-26-355735 · ownership.xml · derivative · entry 2

Tripuraneni Radhika · CIK 0001761114 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 40,000 shares

Expires 2034-07-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: The option is fully vested.

SEC source: 0001193125-26-355735 · ownership.xml · nonDerivative · entry 1

Tripuraneni Radhika · CIK 0001761114 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 40,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001193125-26-294552 · ownership.xml · derivative · entry 1

Gheuens Sarah · CIK 0001881190 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 32,341

Underlying: Common Stock · 32,341 shares

Expires 2036-07-01

F1 · derivative.exercise_date: The option vests in full upon the earlier to occur of (i) July 1, 2027 or (ii) the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's continued service on the Board of Directors of the Issuer.

SEC source: 0001193125-26-294561 · ownership.xml · derivative · entry 1

CAIN CHRISTOPHER W. · CIK 0001817733 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 32,341

Underlying: Common Stock · 32,341 shares

Expires 2036-07-01

F1 · derivative.exercise_date: The option vests in full upon the earlier to occur of (i) July 1, 2027 or (ii) the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's continued service on the Board of Directors of the Issuer.

F2 · ownership.nature: Under the Reporting Person's arrangement with Fairmount Funds Management LLC (the "Adviser"), the Reporting Person holds the option for one or more investment vehicles managed by the Adviser (each, a "Fairmount Fund"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received from the option for the benefit of such Fairmount Fund. The Reporting Person therefore disclaims beneficial ownership of the option and underlying common stock.

SEC source: 0001193125-26-294546 · ownership.xml · derivative · entry 1

Morris Arlene · CIK 0001362520 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 32,341

Underlying: Common Stock · 32,341 shares

Expires 2036-07-01

F1 · derivative.exercise_date: The option vests in full upon the earlier to occur of (i) July 1, 2027 or (ii) the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's continued service on the Board of Directors of the Issuer.

SEC source: 0001193125-26-294560 · ownership.xml · derivative · entry 1

Ajer Jeffrey Robert · CIK 0001557533 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 32,341

Underlying: Common Stock · 32,341 shares

Expires 2036-07-01

F1 · derivative.exercise_date: The option vests in full upon the earlier to occur of (i) July 1, 2027 or (ii) the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's continued service on the Board of Directors of the Issuer.

SEC source: 0001193125-26-294556 · ownership.xml · derivative · entry 1

Moses Jennifer K. · CIK 0001706667 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 32,341

Underlying: Common Stock · 32,341 shares

Expires 2036-07-01

F1 · derivative.exercise_date: The option vests in full upon the earlier to occur of (i) July 1, 2027 or (ii) the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's continued service on the Board of Directors of the Issuer.

SEC source: 0001193125-26-294547 · ownership.xml · derivative · entry 1

Kiselak Tomas · CIK 0001830177 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 32,341

Underlying: Common Stock · 32,341 shares

Expires 2036-07-01

F1 · derivative.exercise_date: The option vests in full upon the earlier to occur of (i) July 1, 2027 or (ii) the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's continued service on the Board of Directors of the Issuer.

F2 · ownership.nature: Under the Reporting Person's arrangement with Fairmount Funds Management LLC (the "Adviser"), the Reporting Person holds the option for one or more investment vehicles managed by the Adviser (each, a "Fairmount Fund"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received from the option for the benefit of such Fairmount Fund. The Reporting Person therefore disclaims beneficial ownership of the option and underlying common stock.

SEC source: 0001104659-26-060294 · tm2614357-1_4seq1.xml · nonDerivative · entry 1

Fairmount Funds Management LLC · CIK 0001802528 · Director · 10% owner

Fairmount Healthcare Fund II GP LLC · CIK 0001830382 · Director · 10% owner

Fairmount Healthcare Fund II L.P. · CIK 0001769651 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Fairmount Healthcare Fund II L.P.

Disclosed balance after: 5,090,928

F1 · ownership.nature: Fairmount Funds Management LLC ("Fairmount") and Fairmount Healthcare Fund II GP LLC ("Fairmount GP II") have voting power and investment power over the securities held by Fairmount Healthcare Fund II LP ("Fund II"). They disclaim beneficial ownership of securities held by Fund II for purposes of Rule 16a-1(a)(2), except to the extent of their pecuniary interest therein.

SEC source: 0001193125-26-092071 · ownership.xml · derivative · entry 5

Harmon Seth · CIK 0001993300 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,801

Underlying: Common Stock · 6,267 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each Restricted Stock Unit (RSU) represents a contingent right to receive one share of common stock of the Issuer.

F4 · derivative.exercise_date: The RSUs vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, March 3, 2025, subject to the Reporting Person's continued service to Issuer through each vesting date.

F4 · derivative.expiration_date: The RSUs vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, March 3, 2025, subject to the Reporting Person's continued service to Issuer through each vesting date.

SEC source: 0001193125-26-092071 · ownership.xml · nonDerivative · entry 2

Harmon Seth · CIK 0001993300 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,790

F5 · balance_after: Includes 903 shares acquired on March 17, 2025 under Viridian Therapeutics, Inc.'s 2016 Employee Stock Purchase Plan and 1,000 shares acquired on September 17, 2025 under Viridian Therapeutics, Inc.'s 2025 Employee Stock Purchase Plan in transactions that were exempt under Rule 16b-3(c).

SEC source: 0001193125-26-092071 · ownership.xml · nonDerivative · entry 1

Harmon Seth · CIK 0001993300 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,881

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · price: Each Restricted Stock Unit (RSU) represents a contingent right to receive one share of common stock of the Issuer.

F5 · balance_after: Includes 903 shares acquired on March 17, 2025 under Viridian Therapeutics, Inc.'s 2016 Employee Stock Purchase Plan and 1,000 shares acquired on September 17, 2025 under Viridian Therapeutics, Inc.'s 2025 Employee Stock Purchase Plan in transactions that were exempt under Rule 16b-3(c).

SEC source: 0001193125-26-092074 · ownership.xml · derivative · entry 5

Tousignant Jennifer · CIK 0002010978 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,510

Underlying: Common Stock · 5,169 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each Restricted Stock Unit (RSU) represents a contingent right to receive one share of common stock of the Issuer.

F4 · derivative.exercise_date: The RSUs vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, March 3, 2025, subject to the Reporting Person's continued service to Issuer through each vesting date.

F4 · derivative.expiration_date: The RSUs vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, March 3, 2025, subject to the Reporting Person's continued service to Issuer through each vesting date.

SEC source: 0001193125-26-092074 · ownership.xml · nonDerivative · entry 2

Tousignant Jennifer · CIK 0002010978 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,445

SEC source: 0001193125-26-092074 · ownership.xml · nonDerivative · entry 1

Tousignant Jennifer · CIK 0002010978 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,169

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · price: Each Restricted Stock Unit (RSU) represents a contingent right to receive one share of common stock of the Issuer.

SEC source: 0001193125-26-092040 · ownership.xml · derivative · entry 5

Beetham Thomas W. · CIK 0001741382 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 28,227

Underlying: Common Stock · 9,409 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each Restricted Stock Unit (RSU) represents a contingent right to receive one share of common stock of the Issuer.

F4 · derivative.exercise_date: The RSUs vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, March 3, 2025, subject to the Reporting Person's continued service to Issuer through each vesting date.

F4 · derivative.expiration_date: The RSUs vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, March 3, 2025, subject to the Reporting Person's continued service to Issuer through each vesting date.

SEC source: 0001193125-26-092040 · ownership.xml · nonDerivative · entry 2

Beetham Thomas W. · CIK 0001741382 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,271

F5 · balance_after: Includes 1,000 shares acquired under Viridian Therapeutics, Inc.'s 2016 Employee Stock Purchase Plan (the "ESPP") on March 17, 2025 in transactions that were exempt under Rule 16b-3(c).

SEC source: 0001193125-26-092040 · ownership.xml · nonDerivative · entry 1

Beetham Thomas W. · CIK 0001741382 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,409

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · price: Each Restricted Stock Unit (RSU) represents a contingent right to receive one share of common stock of the Issuer.

F5 · balance_after: Includes 1,000 shares acquired under Viridian Therapeutics, Inc.'s 2016 Employee Stock Purchase Plan (the "ESPP") on March 17, 2025 in transactions that were exempt under Rule 16b-3(c).

SEC source: 0001193125-26-092036 · ownership.xml · derivative · entry 5

Mahoney Stephen F. · CIK 0001741389 · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 55,071

Underlying: Common Stock · 18,357 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each Restricted Stock Unit (RSU) represents a contingent right to receive one share of common stock of the Issuer.

F4 · derivative.exercise_date: The RSUs vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, March 3, 2025, subject to the Reporting Person's continued service to Issuer through each vesting date.

F4 · derivative.expiration_date: The RSUs vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, March 3, 2025, subject to the Reporting Person's continued service to Issuer through each vesting date.

SEC source: 0001193125-26-092036 · ownership.xml · nonDerivative · entry 2

Mahoney Stephen F. · CIK 0001741389 · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 33,130

F5 · balance_after: Includes 1,000 shares acquired under Viridian Therapeutics, Inc.'s 2016 Employee Stock Purchase Plan (the "ESPP") on March 17, 2025 in transactions that were exempt under Rule 16b-3(c).

SEC source: 0001193125-26-092036 · ownership.xml · nonDerivative · entry 1

Mahoney Stephen F. · CIK 0001741389 · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 40,757

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · price: Each Restricted Stock Unit (RSU) represents a contingent right to receive one share of common stock of the Issuer.

F5 · balance_after: Includes 1,000 shares acquired under Viridian Therapeutics, Inc.'s 2016 Employee Stock Purchase Plan (the "ESPP") on March 17, 2025 in transactions that were exempt under Rule 16b-3(c).

SEC source: 0001193125-26-099023 · ownership.xml · nonDerivative · entry 1

Harmon Seth · CIK 0001993300 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,850

F1 · shares: This amendment corrects the number of shares and price sold to cover taxes on the initial Form 4 filed on March 4, 2026, as well as the resulting total number of shares beneficially owned following all transactions reported in the initial Form 4.

F1 · balance_after: This amendment corrects the number of shares and price sold to cover taxes on the initial Form 4 filed on March 4, 2026, as well as the resulting total number of shares beneficially owned following all transactions reported in the initial Form 4.

SEC source: 0001193125-26-099014 · ownership.xml · nonDerivative · entry 1

Beetham Thomas W. · CIK 0001741382 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,361

F1 · shares: This amendment corrects the number of shares and price sold to cover taxes on the initial Form 4 filed on March 4, 2026, as well as the resulting total number of shares beneficially owned following all transactions reported in the initial Form 4.

F1 · balance_after: This amendment corrects the number of shares and price sold to cover taxes on the initial Form 4 filed on March 4, 2026, as well as the resulting total number of shares beneficially owned following all transactions reported in the initial Form 4.

SEC source: 0001193125-26-099008 · ownership.xml · nonDerivative · entry 1

Tousignant Jennifer · CIK 0002010978 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,494

F1 · shares: This amendment corrects the number of shares and price sold to cover taxes on the initial Form 4 filed on March 4, 2026, as well as the resulting total number of shares beneficially owned following all transactions reported in the initial Form 4.

F1 · balance_after: This amendment corrects the number of shares and price sold to cover taxes on the initial Form 4 filed on March 4, 2026, as well as the resulting total number of shares beneficially owned following all transactions reported in the initial Form 4.

SEC source: 0001193125-26-099007 · ownership.xml · nonDerivative · entry 1

Mahoney Stephen F. · CIK 0001741389 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 33,349

F1 · shares: This amendment corrects the number of shares and price sold to cover taxes on the initial Form 4 filed on March 4, 2026, as well as the resulting total number of shares beneficially owned following all transactions reported in the initial Form 4.

F1 · balance_after: This amendment corrects the number of shares and price sold to cover taxes on the initial Form 4 filed on March 4, 2026, as well as the resulting total number of shares beneficially owned following all transactions reported in the initial Form 4.

SEC source: 0001193125-26-092071 · ownership.xml · derivative · entry 4

Harmon Seth · CIK 0001993300 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,550

Underlying: Common Stock · 20,550 shares

Expires not disclosed

F2 · derivative.exercise_price: Each Restricted Stock Unit (RSU) represents a contingent right to receive one share of common stock of the Issuer.

F3 · derivative.exercise_date: The RSUs vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, March 2, 2026, subject to the Reporting Person's continued service to Issuer through each vesting date.

F3 · derivative.expiration_date: The RSUs vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, March 2, 2026, subject to the Reporting Person's continued service to Issuer through each vesting date.

SEC source: 0001193125-26-092071 · ownership.xml · derivative · entry 3

Harmon Seth · CIK 0001993300 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 102,850

Underlying: Common Stock · 102,850 shares

Expires 2036-03-02

F1 · derivative.exercise_date: The option vests and becomes exercisable in 48 equal monthly installments following the date of the grant, subject to the Reporting Person's continued service to Issuer through each vesting date. The date of the grant is March 2, 2026.

SEC source: 0001193125-26-092074 · ownership.xml · derivative · entry 4

Tousignant Jennifer · CIK 0002010978 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,850

Underlying: Common Stock · 23,850 shares

Expires not disclosed

F2 · derivative.exercise_price: Each Restricted Stock Unit (RSU) represents a contingent right to receive one share of common stock of the Issuer.

F3 · derivative.exercise_date: The RSUs vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, March 2, 2026, subject to the Reporting Person's continued service to Issuer through each vesting date.

F3 · derivative.expiration_date: The RSUs vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, March 2, 2026, subject to the Reporting Person's continued service to Issuer through each vesting date.

SEC source: 0001193125-26-092074 · ownership.xml · derivative · entry 3

Tousignant Jennifer · CIK 0002010978 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 119,300

Underlying: Common Stock · 119,300 shares

Expires 2036-03-02

F1 · derivative.exercise_date: The option vests and becomes exercisable in 48 equal monthly installments following the date of the grant, subject to the Reporting Person's continued service to Issuer through each vesting date. The date of the grant is March 2, 2026.

SEC source: 0001193125-26-092040 · ownership.xml · derivative · entry 4

Beetham Thomas W. · CIK 0001741382 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 35,300

Underlying: Common Stock · 35,300 shares

Expires not disclosed

F2 · derivative.exercise_price: Each Restricted Stock Unit (RSU) represents a contingent right to receive one share of common stock of the Issuer.

F3 · derivative.exercise_date: The RSUs vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, March 2, 2026, subject to the Reporting Person's continued service to Issuer through each vesting date.

F3 · derivative.expiration_date: The RSUs vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, March 2, 2026, subject to the Reporting Person's continued service to Issuer through each vesting date.

SEC source: 0001193125-26-092040 · ownership.xml · derivative · entry 3

Beetham Thomas W. · CIK 0001741382 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 176,550

Underlying: Common Stock · 176,550 shares

Expires 2036-03-02

F1 · derivative.exercise_date: The option vests and becomes exercisable in 48 equal monthly installments following the date of the grant, subject to the Reporting Person's continued service to Issuer through each vesting date. The date of the grant is March 2, 2026.

SEC source: 0001193125-26-092036 · ownership.xml · derivative · entry 4

Mahoney Stephen F. · CIK 0001741389 · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 111,900

Underlying: Common Stock · 111,900 shares

Expires not disclosed

F2 · derivative.exercise_price: Each Restricted Stock Unit (RSU) represents a contingent right to receive one share of common stock of the Issuer.

F3 · derivative.exercise_date: The RSUs vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, March 2, 2026, subject to the Reporting Person's continued service to Issuer through each vesting date.

F3 · derivative.expiration_date: The RSUs vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, March 2, 2026, subject to the Reporting Person's continued service to Issuer through each vesting date.

SEC source: 0001193125-26-092036 · ownership.xml · derivative · entry 3

Mahoney Stephen F. · CIK 0001741389 · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 559,600

Underlying: Common Stock · 559,600 shares

Expires 2036-03-02

F1 · derivative.exercise_date: The option vests and becomes exercisable in 48 equal monthly installments following the date of the grant, subject to the Reporting Person's continued service to Issuer through each vesting date. The date of the grant is March 2, 2026.

SEC source: 0001193125-26-092028 · ownership.xml · derivative · entry 2

Tripuraneni Radhika · CIK 0001761114 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 19,150

Underlying: Common Stock · 19,150 shares

Expires not disclosed

F2 · derivative.exercise_price: Each Restricted Stock Unit (RSU) represents a contingent right to receive one share of common stock of the Issuer.

F3 · derivative.exercise_date: The RSUs vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, March 2, 2026, subject to the Reporting Person's continued service to Issuer through each vesting date.

F3 · derivative.expiration_date: The RSUs vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, March 2, 2026, subject to the Reporting Person's continued service to Issuer through each vesting date.

SEC source: 0001193125-26-092028 · ownership.xml · derivative · entry 1

Tripuraneni Radhika · CIK 0001761114 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 95,800

Underlying: Common Stock · 95,800 shares

Expires 2036-03-02

F1 · derivative.exercise_date: The option vests and becomes exercisable in 48 equal monthly installments following the date of the grant, subject to the Reporting Person's continued service to Issuer through each vesting date. The date of the grant is March 2, 2026.

SEC source: 0001193125-26-001097 · ownership.xml · nonDerivative · entry 1

Tousignant Jennifer · CIK 0002010978 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

F1 · shares: Consists of shares purchased under the Issuer's employee stock purchase plan.

SEC source: 0001104659-25-102606 · tm2529526-1_4seq1.xml · nonDerivative · entry 1

Fairmount Funds Management LLC · CIK 0001802528 · Director · 10% owner

Fairmount Healthcare Fund II GP LLC · CIK 0001830382 · Director · 10% owner

Fairmount Healthcare Fund II L.P. · CIK 0001769651 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · Fairmount Healthcare Fund II LP

Disclosed balance after: 3,914,458

F1 · ownership.nature: Fairmount Funds Management LLC ("Fairmount") and Fairmount Healthcare Fund II GP LLC ("Fairmount GP II") have voting power and investment power over the securities held by Fairmount Healthcare Fund II LP ("Fund II"). They disclaim beneficial ownership of securities held by Fund II for purposes of Rule 16a-1(a)(2), except to the extent of their pecuniary interest therein.

SEC source: 0000950170-25-093099 · ownership.xml · derivative · entry 1

Gheuens Sarah · CIK 0001881190 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 21,000

Underlying: Common Stock · 21,000 shares

Expires 2035-07-01

F1 · derivative.exercise_date: The option vests in full upon the earlier to occur of (i) July 1, 2026 or (ii) the Issuer's 2026 annual meeting of stockholders, subject to the Reporting Person's continued service on the Board of Directors of the Issuer.

SEC source: 0000950170-25-093118 · ownership.xml · derivative · entry 1

CAIN CHRISTOPHER W. · CIK 0001817733 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 21,000

Underlying: Common Stock · 21,000 shares

Expires 2035-07-01

F1 · derivative.exercise_date: The option vests in full upon the earlier to occur of (i) July 1, 2026 or (ii) the Issuer's 2026 annual meeting of stockholders, subject to the Reporting Person's continued service on the Board of Directors of the Issuer.

F2 · ownership.nature: Under the Reporting Person's arrangement with Fairmount Funds Management LLC (the "Adviser"), the Reporting Person holds the option for one or more investment vehicles managed by the Adviser (each, a "Fairmount Fund"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received from the option for the benefit of such Fairmount Fund. The Reporting Person therefore disclaims beneficial ownership of the option and underlying common stock.

SEC source: 0000950170-25-093107 · ownership.xml · derivative · entry 1

Morris Arlene · CIK 0001362520 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 21,000

Underlying: Common Stock · 21,000 shares

Expires 2035-07-01

F1 · derivative.exercise_date: The option vests in full upon the earlier to occur of (i) July 1, 2026 or (ii) the Issuer's 2026 annual meeting of stockholders, subject to the Reporting Person's continued service on the Board of Directors of the Issuer.

SEC source: 0000950170-25-093102 · ownership.xml · derivative · entry 1

Ajer Jeffrey Robert · CIK 0001557533 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 21,000

Underlying: Common Stock · 21,000 shares

Expires 2035-07-01

F1 · derivative.exercise_date: The option vests in full upon the earlier to occur of (i) July 1, 2026 or (ii) the Issuer's 2026 annual meeting of stockholders, subject to the Reporting Person's continued service on the Board of Directors of the Issuer.

SEC source: 0000950170-25-093111 · ownership.xml · derivative · entry 1

Kiselak Tomas · CIK 0001830177 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 21,000

Underlying: Common Stock · 21,000 shares

Expires 2035-07-01

F1 · derivative.exercise_date: The option vests in full upon the earlier to occur of (i) July 1, 2026 or (ii) the Issuer's 2026 annual meeting of stockholders, subject to the Reporting Person's continued service on the Board of Directors of the Issuer.

F2 · ownership.nature: Under the Reporting Person's arrangement with Fairmount Funds Management LLC (the "Adviser"), the Reporting Person holds the option for one or more investment vehicles managed by the Adviser (each, a "Fairmount Fund"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received from the option for the benefit of such Fairmount Fund. The Reporting Person therefore disclaims beneficial ownership of the option and underlying common stock.

SEC source: 0000950170-25-093098 · ownership.xml · derivative · entry 1

Moses Jennifer K. · CIK 0001706667 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 21,000

Underlying: Common Stock · 21,000 shares

Expires 2035-07-01

F1 · derivative.exercise_date: The option vests in full upon the earlier to occur of (i) July 1, 2026 or (ii) the Issuer's 2026 annual meeting of stockholders, subject to the Reporting Person's continued service on the Board of Directors of the Issuer.

SEC source: 0001104659-25-058580 · tm2517665d1_4seq1.xml · derivative · entry 4

Fairmount Funds Management LLC · CIK 0001802528 · Director · 10% owner

Fairmount Healthcare Fund II GP LLC · CIK 0001830382 · Director · 10% owner

Fairmount Healthcare Fund II L.P. · CIK 0001769651 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By: Peter Harwin

Disclosed balance after: 0

Underlying: Common Stock · 12,500 shares

Expires 2025-06-10

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · ownership.direct: Under Mr. Harwin's arrangement with Fairmount, Mr. Harwin held options received as director compensation from the Issuer for one or more investment vehicles managed by Fairmount (each, a "Fairmount Fund"). Mr. Harwin is obligated to turn over to Fairmount any net cash or stock received from such options for the benefit of such Fairmount Fund. Mr. Harwin therefore disclaims beneficial ownership of the option and underlying common stock. Fairmount disclaims beneficial ownership of any of the reported securities, except to the extent of its pecuniary interest therein.

SEC source: 0001104659-25-058580 · tm2517665d1_4seq1.xml · nonDerivative · entry 2

Fairmount Funds Management LLC · CIK 0001802528 · Director · 10% owner

Fairmount Healthcare Fund II GP LLC · CIK 0001830382 · Director · 10% owner

Fairmount Healthcare Fund II L.P. · CIK 0001769651 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · Fairmount Healthcare Fund II LP

Disclosed balance after: 3,459,913

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · ownership.nature: Fairmount Funds Management LLC ("Fairmount") and Fairmount Healthcare Fund II GP LLC ("Fairmount GP II") have voting power and investment power over the securities held by Fairmount Healthcare Fund II LP ("Fund II"). They disclaim beneficial ownership of securities held by Fund II for purposes of Rule 16a-1(a)(2), except to the extent of their pecuniary interest therein.

SEC source: 0001104659-25-058580 · tm2517665d1_4seq1.xml · derivative · entry 3

Fairmount Funds Management LLC · CIK 0001802528 · Director · 10% owner

Fairmount Healthcare Fund II GP LLC · CIK 0001830382 · Director · 10% owner

Fairmount Healthcare Fund II L.P. · CIK 0001769651 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By: Peter Harwin

Disclosed balance after: 0

Underlying: Common Stock · 1,600 shares

Expires 2025-06-10

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: Beginning on October 27, 2020, the option vested monthly over a three-year period, subject to Peter Harwin's continued service to the Issuer. Mr. Harwin, a Managing Member of Fairmount and Fairmount GP II, served on the Issuer's Board of Directors through March 10, 2025.

F3 · ownership.direct: Under Mr. Harwin's arrangement with Fairmount, Mr. Harwin held options received as director compensation from the Issuer for one or more investment vehicles managed by Fairmount (each, a "Fairmount Fund"). Mr. Harwin is obligated to turn over to Fairmount any net cash or stock received from such options for the benefit of such Fairmount Fund. Mr. Harwin therefore disclaims beneficial ownership of the option and underlying common stock. Fairmount disclaims beneficial ownership of any of the reported securities, except to the extent of its pecuniary interest therein.